Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Active Controlled, Parallel Group, Multicentre, Two-Phase, Open-Label Study Comparing the Safety and Immunogenicity of Insugen R and Insugen N with Actrapid and Insulatard in Patients with Type 1 Diabetes Mellitus.

Next Previous
Trial Profile

A Randomized, Active Controlled, Parallel Group, Multicentre, Two-Phase, Open-Label Study Comparing the Safety and Immunogenicity of Insugen R and Insugen N with Actrapid and Insulatard in Patients with Type 1 Diabetes Mellitus.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jan 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin (Primary) ; Insulin suspension isophane (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics; Registrational
  • Sponsors Biocon

Most Recent Events

  • 04 Jul 2012 Actual end date (19 Jan 2012) added as reported by Clinical Trials Registry - India record.
  • 04 Jul 2012 Status changed from recruiting to completed as reported by Clinical Trials Registry - India record.
  • 30 Jun 2012 Planned end date calculated from estimated duration in EudraCT record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top